MedicineNews.net - Medical Updates

Opdivo plus Yervoy combined with two cycles of chemotherapy as first-line treatment of metastatic non-small cell lung cancer, positive CHMP opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has recommended approval of Opdivo ( Nivolumab ) plus Yervoy ( Ipilimumab ) with two cycles of Plat ... read article

FDA has granted accelerated approval to Zepzelca for metastatic small cell lung cancer

The FDA ( Food and Drug Administration ) has granted accelerated approval to Zepzelca ( Lurbinectedin ) for adult patients with metastatic small cell lung cancer ( SCLC ) with disease progression on o ... read article

CheckMate -577: Nivolumab as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer, has met primary endpoint of disease-free survival

The phase 3 CheckMate -577 trial evaluating Nivolumab ( Opdivo ) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction ( GEJ ) cancer met its primary endpoint of di ... read article

SELECTION trial: Filgotinib 200 mg has demonstrated greater efficacy compared with placebo in induction and maintenance of remission in patients with moderately to severely active ulcerative colitis

Results from SELECTION, a randomized, double-blind, placebo-controlled, phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor Filgotini ... read article

Venetoclax plus Azacitidine has demonstrated overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients

The results from the VIALE-A trial, which has demonstrated that previously-untreated patients with acute myeloid leukemia ( AML ) who were ineligible for intensive chemotherapy treated with Venetoclax ... read article

Osimertinib: ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer

The ADAURA phase III trial for Osimertinib ( Tagrisso ) in the adjuvant treatment of patients with stage IB, II and IIIA epidermal growth factor receptor-mutated ( EGFRm ) non-small cell lung cancer ( ... read article

Keytruda monotherapy in patients whose cancers are tumor mutational burden-high who have progressed following prior treatment: sBLA accepted by FDA

The FDA ( U.S. Food and Drug Administration ) has accepted and granted priority review for a new supplemental Biologics License Application ( sBLA ) for Keytruda ( Pembrolizumab ), an anti-PD-1 therap ... read article

Squamous cell carcinoma of the head and neck: JAVELIN Head and Neck 100 discontinued due to efficacy doubts

An update from the phase III JAVELIN Head and Neck 100 study evaluating Avelumab ( Bavencio ) in addition to chemoradiotherapy ( CRT ) versus standard-of-care CRT in patients with untreated locally ad ... read article

Possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR, FDA continues to evaluate the trial results

The FDA ( U.S. Food and Drug Administration ) has alerted the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine Be ... read article

Loncastuximab tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma

Positive results from the pivotal 145-patient phase 2 clinical trial of Loncastuximab tesirine ( ADCT-402 ) for the treatment of relapsed or refractory diffuse large B-cell lymphoma ( DLBCL ) were an ... read article

Nivolumab plus Ipilimumab has shown continued survival benefit at 42-month follow-up in patients with previously untreated advanced or metastatic renal cell carcinoma

Updated results from the phase 3 CheckMate -214 study evaluating the combination of Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib( Sutent ) in patients with previously untreated adv ... read article

Muscle-invasive urothelial cancer: Atezolizumab as adjuvant monotherapy treatment did not meet its primary endpoint in IMvigor010

The phase III IMvigor010 study evaluating Atezolizumab ( Tecentriq ) as an adjuvant ( after surgery ) monotherapy treatment did not meet its primary endpoint of disease-free survival ( DFS ) compared ... read article

FIREFISH trial in infants with type 1 spinal muscular atrophy: Risdiplam has demonstrated motor improvement

Positive results from the pivotal Part 2 of the FIREFISH study, evaluating Risdiplam in infants aged 1-7 months with type 1 spinal muscular atrophy ( SMA ) were announced. The primary outcome measu ... read article

Keytruda in patients with high-risk, non-muscle invasive bladder cancer

The FDA ( U.S. Food and Drug Administration ) has accepted and granted priority review for a new supplemental Biologics License Application ( sBLA ) for Keytruda ( Pembrolizumab ), an anti-PD-1 therap ... read article

Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

The EMA's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Kadcyla ( Trastuzumab emtansine ) for the adjuvant treatment of adult patients with HER2-positive earl ... read article